Newsroom.

Australia's premier life science investment event, AusBioInvest 2024, is in Melbourne today. It features industry-leading international speakers, keynote addresses from global investment leaders, and pitch presentations from top biotechnology companies.

This year, AusBiotech’s one-day AusBioInvest event is welcoming more than 260 delegates from Australia's thriving life science companies, Australian and global investors, including venture capital firms, private equity firms, and individuals, as well as research analysts and brokers, industry executives, and major global stakeholders.

Rebekah Casiddy, AusBiotech CEO, said Australia's biggest week in biotech is officially here, with AusBioInvest 2024 starting today and the official AusBiotech 2024 three-day programme starting tomorrow.

"AusBioInvest is just one way that AusBiotech continues to ensure our investment programmes are designed to the evolving needs of our members at all stages of capital raising, with a laser focus on creating meaningful connections, "she said.

The AusBioInvest programme offers insights and opportunities, beginning with an opening keynote by Dr. Eric Shiozaki, Partner at DCVC Bio, exploring the transformative role of AI and technology in biotech, and sharing valuable perspectives on what drives success from an investor’s viewpoint.

Followed by thought-provoking panels featuring Sarah Meibusch, Partner at OneVentures, who will unpack investment trends and diverse funding options—public, private, debt, and equity; and Rhenu Bhuller, AusBiotech's Global Investment Lead, who will join experts Matt McNamara of Horizon 3 Healthcare and Bianca Ogden of Platinum Asset Management to discuss how investors and founders can effectively collaborate to drive biotech innovation.

The presentations at AusBioInvest, featuring 26 innovative private and listed Australian biotech companies, represent a significant opportunity for investors and potential partners to connect directly with companies seeking funding and collaborative development.

Presenting companies include Amplia Therapeutics Limited (ASX: ATX), Arovella Therapeutics (ASX: ALA), Atticus Medical, BiomeBank, Blinklab Limited (ASX:BB1), Cambium Bio Limited (ASX: CMB), Carina Biotech Limited, Chimeric Therapeutics (ASX: CHM), EBR Systems (ASX: EBR), Evithé Biotechnology, FivepHusion, Immuron Limited (ASX: IMC), Imugene (ASX: IMU), Invion Limited (ASX: IVX), Neurizon Therapeutics (ASX: NUZ), Neurotologix, Novapep, Nyrada Inc. (ASX: NYR), Esfam Biotech, Polyactiva Pty Ltd, Servatus Ltd, Syntara (ASX: SNT) and Vaxxas.

"Part of AusBiotech’s role is knowledge sharing and connection building including with the investment community. Our ‘Invest’ events help great Australian companies to attract capital while assisting investors in connecting with innovative Australian companies that may offer high-value returns,” said Rebekah.

"We are proud of our work to put Australia's homegrown innovation on the global stage with local and international investors.”

AusBioInvest officially marks the beginning of Australia's biggest week in biotech, with AusBiotech flagship conference, AusBiotech 2024, commencing tomorrow in Melbourne from 30 October – 1 November.

About AusBiotech

AusBiotech is Australia's leading national and global advocate for life sciences, working to help its more than 3000 members thrive by shaping policy, creating connections, and fostering knowledge sharing. With an unrivalled national convening power, AusBiotech supports its members’ growth by building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.

-ENDS-

Media enquiries: Emma Boscheinen, Director of Communications, AusBiotech, eboscheinen@ausbiotech.org / M: +61 (0) 437 075 209